The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
JUNO THERAPEUTICS, INC. COMMON STOCK 48205A109 68,516 2,205,926 SH   OTR 1,2 1,602,562 603,364 0
MABVAX THERAPEUTICS HOLDINGS, INC. COMMON STOCK 55414P108 119 197,641 SH   OTR 1,2 197,641 0 0
ADMA BIOLOGICS, INC. COMMON STOCK 000899104 9,302 1,433,304 SH   OTR 1,2 1,433,304 0 0